Results of a Multilevel Intervention Trial to Increase Human Papillomavirus (HPV) Vaccine Uptake among Adolescent Girls

Electra D Paskett, Jessica L Krok-Schoen, Michael L Pennell, Cathy M Tatum, Paul L Reiter, Juan Peng, Brittany M Bernardo, Rory C Weier, Morgan S Richardson, Mira L Katz, Electra D Paskett, Jessica L Krok-Schoen, Michael L Pennell, Cathy M Tatum, Paul L Reiter, Juan Peng, Brittany M Bernardo, Rory C Weier, Morgan S Richardson, Mira L Katz

Abstract

Background: Uptake of the human papillomavirus (HPV) vaccine is low in Appalachian Ohio and areas with high cervical cancer rates.

Methods: We conducted a group-randomized trial among 12 counties in Appalachian Ohio randomized to receive either an HPV vaccine (intervention counties) or influenza vaccine (comparison counties) multilevel intervention (MLI). Parents (n = 337) who had a daughter aged 9 to 17 years who had not received the HPV vaccine were recruited from commercial lists. Clinics (N = 24) and 119 providers from these clinics were also recruited. The primary outcome was medical record-confirmed receipt of the first shot of the HPV vaccine 3 months after receiving the intervention among daughters of parents enrolled in the study. Secondary outcomes included receipt of the first HPV vaccine shot by 6 months and changes in provider knowledge.

Results: According to medical records, 10 (7.7%) daughters of intervention participants received the first shot of the HPV vaccine within 3 months of being sent the intervention materials compared with 4 (3.2%) daughters of comparison group participants (P = 0.061). By 6 months, 17 (13.1%) daughters of intervention participants received the first HPV vaccine shot compared with eight (6.5%) daughters of comparison group participants (P = 0.002). Provider knowledge about HPV increased (P < 0.001, from baseline to after education).

Conclusions: The MLI increased uptake of the HPV vaccine among girls aged 9 to 17 years; however, uptake was low.

Impact: To improve HPV vaccine uptake, attention to additional levels of influence (e.g., policy, community) and more elements within levels (e.g., reminders, automated prompts) may be needed. Cancer Epidemiol Biomarkers Prev; 25(4); 593-602. ©2016 AACR SEE ALL ARTICLES IN THIS CEBP FOCUS SECTION, "MULTILEVEL APPROACHES TO ADDRESSING CANCER HEALTH DISPARITIES".

Conflict of interest statement

Conflict of Interest Statement: E.D. Paskett has received research grants from Merck Sharp & Dohme Corp. P.L. Reiter has received research grants from Merck Sharp & Dohme Corp. and Cervical Cancer-Free America, via an unrestricted educational grant from GlaxoSmithKline. These funds were not used to support this research study.

©2016 American Association for Cancer Research.

Figures

Figure 1. CONSORT Diagram of Parent Participants…
Figure 1. CONSORT Diagram of Parent Participants by Intervention Group
Figure 2. CONSORT Diagram of Clinic and…
Figure 2. CONSORT Diagram of Clinic and Provider Participants by Intervention Group

References

    1. Schiffman M, Hildesheim A. Cervical cancer. In: Schottenfeld D, Fraumeni J, editors. Cancer Epidemiology and Prevention. 3. New York: Oxford; 2006. pp. 1044–67.
    1. Mayne S, Morse D, Winn D. Cancers of the oral cavity and pharynx. In: Schottenfeld D, Fraumeni J, editors. Cancer Epidemiology and Prevention. 3. New York: Oxford; 2006. pp. 674–96.
    1. Frisch M, Melbye M. Anal cancer. In: Schottenfeld D, Fraumeni J, editors. Cancer Epidemiology and Prevention. 3. New York: Oxford; 2006. pp. 830–40.
    1. Madeline M, Daling J. Cancers of the vulva and vagina. In: Schottenfeld D, Fraumeni J, editors. Cancer Epidemiology and Prevention. 3. New York: Oxford; 2006. pp. 1068–74.
    1. Wideroff L, Schottenfeld D. Penile cancer. In: Schottenfeld D, Fraumeni J, editors. Cancer Epidemiology and Prevention. 3. New York: Oxford; 2006. pp. 1166–72.
    1. Quadrivalent human papillomavirus vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep. 2007;56:1–24.
    1. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2014;63:1–30.
    1. U.S. Food and Drug Administration (FDA) [Accessed October 26, 2015];Vaccines, blood, and biologics: Human papillomavirus vaccine. Available: . Updated January 29, 2015.
    1. Recommendations on the use of quadrivalent human papillomavirus vaccine in males- Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1705–8.
    1. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377:2085–92.
    1. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11:39–44.
    1. Brotherton JM, Liu B, Donovan B, Kaldor JM, Saville M. Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. Vaccine. 2014;32:592–7.
    1. Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer. 2013;13:10–21.
    1. Limia A, Pachón I. Coverage of human papillomavirus vaccination during the first year of its introduction in Spain. Euro Surveill. 2011;16:1–4.
    1. Hopkins TG, Wood N. Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes. Vaccine. 2013;31:1673–9.
    1. Rahman M, Laz TH, McGrath CJ, Berenson AB. Provider recommendation mediates the relationship between parental human papillomavirus (HPV) vaccine awareness and HPV vaccine initiation and completion among 13-to 17-year-old U.S. adolescent children. Clinical Pediatr. 2015;54:371–5.
    1. American College of Obstetricians and Gynecologists. Human papillomavirus vaccination. Committee opinion No. 47. Obstet Gynecol. 2010;116:800–3.
    1. Centers for Disease Control and Prevention (CDC) FDA Licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep. 2010;59:626–9.
    1. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE. Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006. J Infect Dis. 2011;204:566–73.
    1. Reiter PL, Katz ML, Ruffin MT, Hade EM, DeGraffenreid CR, Patel DA, et al. HPV prevalence among women from Appalachia: results from the CARE project. PLoS One. 2013;8:e74276.
    1. Horner MJ, Altekruse SF, Zou Z, Wideroff L, Katki HA, Stinchcomb DG. U.S. geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiol Biomarkers Prev. 2011;20:591–9.
    1. Reiter PL, Fisher JL, Hudson AG, Tucker TC, Plascak JJ, Paskett ED. Assessing the burden of HPV-related cancers in Appalachia. Human Vaccin Immunother. 2013;9:90–6.
    1. Pollard K, Jacobsen LA. The Appalachian region: a data overview from the 2006-2010 American Community Survey. 2012 Available at: .
    1. PDA, Inc., and the Cecil B. Sheps Center for Health Services Research. Health care costs and access disparities in Appalachia. 2012 Available at: .
    1. Halverson JA. An analysis of disparities in health status and access to health care in the Appalachian region. 2004 Available at: .
    1. Wingo PA, Tucker TC, Jamison PM, Martin H, McLaughlin C, Bayakly R, et al. Cancer in Appalachia, 2001-2003. Cancer. 2008;112:181–92.
    1. Blackley D, Behringer B, Zheng S. Cancer mortality rates in Appalachia: descriptive epidemiology and an approach to explaining differences in outcomes. J Community Health. 2012;37:804–13.
    1. Reiter PL, Katz ML, Paskett ED. Correlates of HPV vaccination among adolescent females from Appalachia and reasons why their parents do not intend to vaccinate. Vaccine. 2013;31:3121–5.
    1. Ruffin MT, Hade EM, Gorsline MR, DeGraffinreid CR, Katz ML, Kobrin SC, Paskett ED. Human papillomavirus vaccine knowledge and hypothetical acceptance among women in Appalachia Ohio. Vaccine. 2012;30:5349–57.
    1. Katz ML, Paskett ED. The process of engaging members from two underserved populations in the development of interventions to promote the uptake of the HPV vaccine. Health Promot Pract. 2015;16:443–53.
    1. Perkins RB, Zisblatt L, Legler A, Trucks E, Hanchate A, Gorin SS. Effectiveness of a provider-focused intervention to improve HPV vaccination rates in boys and girls. Vaccine. 2015;33:1223–9.
    1. Fu LY, Bonhomme LA, Copper SC, Joseph JG, Zimet GD. Educational interventions to increase HPV vaccination acceptance: a systematic review. Vaccine. 2014;32:1901–20.
    1. Janz NK, Becker MH. The health belief model: a decade later. Health Educ Q. 1984;11:1–47.
    1. Ajzen I, Fishbein M. Understanding attitudes and predicting social behavior. Englewood Cliffs, NJ: Prentice-Hall; 1980.
    1. Witte K. Fear control and danger control: a test of the extended parallel process model (EPPM) Commun Monogr. 1994;61:113–34.
    1. French WL, Bell CH. Organizational development: behavioral sciences interventions for organization improvement. Englewood Cliffs, NJ: Prentice-Hall; 1973.
    1. Survey Sampling International [Internet] Shelton, CT. c2015 [updated 2015; cited 2016 Feb 8]. Available from:
    1. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; 2008.
    1. Briss PA, Rodewald LE, Hinman AR, Shefer AM, Strikas RA, Bernier RR, et al. Reviews of the evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. The Task Force on Community and Preventive Services. Am J Prev Med. 2000;18:97–140.
    1. Donner A, Klar N. Design and analysis of cluster randomization trials in health research. New York: Oxford University Press; 2000.
    1. Lichtenstein E, Glasgow RE. Smoking cessation: what have we learned over the last decade. J Consult Clin Psychol. 1992;60:518–27.
    1. Gail MH, Mark SD, Carroll RJ, Green SB, Pee D. On design considerations and randomization based inference for community intervention trials. Stat Med. 1996;15:1069–92.
    1. Aragones A, Bruno DM, Ehrenberg M, Tonda-Salcedo J, Gany FM. Parental education and text messaging reminders as effective community based tools to increase HPV vaccination rates among Mexican American children. Prev Med Rep. 2015;2:554–8.
    1. Parra-Medina D, Morales-Campos DY, Mojica C, Ramirez AG. Promotora outreach, education and navigation support for HPV vaccination to Hispanic women with unvaccinated daughters. J Cancer Educ. 2015;30:353–9.
    1. Rosen LJ, Noach MB, Winickoff JP, Hovell MF. Parental smoking cessation to protect young children: a systematic review and meta-analysis. Pediatrics. 2012;129:141–52.
    1. Berwick DM. Disseminating innovations in health care. JAMA. 2003;289:1969–75.
    1. Paskett ED, McLaughlin JM, Reiter PL, Lehman AM, Rhoda DA, Katz ML, et al. Psychosocial predictors of adherence to risk-appropriate cervical cancer screening guidelines: A cross sectional study of women in Ohio Appalachia participating in the Community Awareness Resources and Education (CARE) project. Prev Med. 2010;50:74–80.
    1. Krok-Schoen JL, Young GS, Pennell ML, Reiter PL, Katz ML, Post DM, et al. Testing Interventions to Motivate and Educate (TIME): A multi-level intervention to improve colorectal cancer screening. Prev Med Rep. 2015;2:306–13.
    1. Chao C, Slezak JM, Coleman KJ, Jacobsen SJ. Papanicolaou screening behavior in mothers and human papillomavirus vaccine uptake in adolescent girls. Am J Public Health. 2009;99:1137.
    1. Vanderpool RC, Cohen EL, Crosby RA, Jones MG, Bates W, Casey BR, et al. “1-2-3 Pap” intervention improves HPV vaccine series completion among Appalachian women. J Commun. 2013;63:95–115.
    1. Davis TC, Fredrickson DD, Kennen EM, Humiston SG, Arnold CL, Quinlin MS, et al. Vaccine risk/benefit communication: effect of an educational package for public health nurses. Health Educa Behav. 2006;33:787–801.
    1. Fiks AG, Grundmeier RW, Mayne S, Song L, Feemster K, Karavite D, et al. Effectiveness of decision support for families, clinicians, or both on HPV vaccine receipt. Pediatrics. 2013;131:1114–24.
    1. Suh CA, Saville A, Daley MF, Glazner JE, Barrow J, Stokley S, et al. Effectiveness and net cost of reminder/recall for adolescent immunizations. Pediatrics. 2012;129:e1437–45.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner